DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19

NIH RePORTER · NIH · N01 · $8,469,477 · view on reporter.nih.gov ↗

Abstract

To support the advanced development of a promising antiviral against a pathogen with pandemic potential. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

Key facts

NIH application ID
10933185
Project number
75N93023C00052-0-9999-1
Recipient
ALIGOS THERAPEUTICS, INC.
Principal Investigator
STANLEY WANG
Activity code
N01
Funding institute
NIH
Fiscal year
2023
Award amount
$8,469,477
Award type
Project period
2023-09-22 → 2026-02-15